Sanofi (ADR)

NYSE: SNY
$49.92
+$0.71 (+1.4%)
Closing price October 22, 2021
According to Merrill Lynch, the health care sector should act as a good hedge against volatility. Even biotech was shown to offer growth at a reasonable price.
The top analyst upgrades, downgrades and other research calls from Friday include Ambarella, Apple, Campbell Soup, Gap, Kinross Gold, Lululemon Athletica and Palo Alto Networks.
The top analyst upgrades, downgrades and other research calls from Wednesday include Blackstone, Ciena, Merck, Tempur Sealy and Universal Display.
24/7 Wall St. takes a look at the ASCO annual meeting each year and picks out the companies that could have the biggest boom or bust at the conference.
If Warren Buffett is considered the greatest investor of the modern era, and if he has held the title of the world's richest man, then maybe he knows a thing or two.
Berkshire Hathaway has released its public equity holdings as of December 31, 2016, and the number of changes in the equity portfolio were nothing short of massive.
2017 could be different for the health care sector. It is very possible that this new administration could lead to more positive trials, FDA approvals, and mergers and acquisitions.
Outside of Warren Buffett being one of the richest men alive and being considered the greatest investor of modern times, there have been many key changes in the Buffett stocks over recent quarters.
The top analyst upgrades, downgrades and initiations seen on Thursday morning include Apple, Callon Petroleum, Hewlett Packard Enterprise, Lululemon Athletica, Nike and Rio Tinto.
At this point, bad news is coming in consistently to the point that any significant piece of good news could catapult Sanofi stock higher, making it an interesting choice for dip-buyers.
In one of the longest running bidding wars in recent times, Pfizer has finally reeled in cancer-drug maker Medivation.
Medivation has been among the top future biotech mergers for quite some time. The problem is that we still have no idea which company will buy Medivation, nor do we know what price.
Here is how the new list of Warren Buffett and Berkshire Hathaway's public share holding looks as of June 30, 2016.
Usually the term "hostile takeover" is an exaggeration, but Sanofi's takeover bid for Medivation actually looks pretty hostile, given that it is now trying to oust the entire board.
Many companies are being discussed as Zika virus winners, but the reality is that many of them are so small or have sketchy histories. This is why we are featuring seven notable companies targeting...